NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 313)
Posted On: 11/05/2019 2:42:20 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Names New Senior Advisor
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, this morning announced the appointment of Gregg Smith as a Senior Advisor for the company. Smith is the founder of Evolution VC Partners (www.EvolutionVCP.com), a New York-based “culture tech” venture investment firm with over 90 portfolio companies. Through his LLC, Smith is acquiring an equity position in LXRP by participating in the company’s recently announced private placement financing of $0.45 units. “I am passionate about creating a smokeless future and recognize that the consumption methods of nicotine and cannabis will change. Lexaria’s technology, DehydraTECH(TM), will completely disrupt and improve the consumption and delivery of oral nicotine, CBD and cannabis,” Senior Advisor Gregg Smith stated in the news release. “Lexaria’s recognition of the recent FDA recognition of certain oral delivery forms of nicotine as ‘less harmful’ to human health than combustible smoking will be a driving force of changing consumer preferences. I expect Lexaria’s technology to play a significant role in that future and I am pleased to advise the management team at Lexaria in defining our leadership strategies.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, this morning announced the appointment of Gregg Smith as a Senior Advisor for the company. Smith is the founder of Evolution VC Partners (www.EvolutionVCP.com), a New York-based “culture tech” venture investment firm with over 90 portfolio companies. Through his LLC, Smith is acquiring an equity position in LXRP by participating in the company’s recently announced private placement financing of $0.45 units. “I am passionate about creating a smokeless future and recognize that the consumption methods of nicotine and cannabis will change. Lexaria’s technology, DehydraTECH(TM), will completely disrupt and improve the consumption and delivery of oral nicotine, CBD and cannabis,” Senior Advisor Gregg Smith stated in the news release. “Lexaria’s recognition of the recent FDA recognition of certain oral delivery forms of nicotine as ‘less harmful’ to human health than combustible smoking will be a driving force of changing consumer preferences. I expect Lexaria’s technology to play a significant role in that future and I am pleased to advise the management team at Lexaria in defining our leadership strategies.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼